JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2014, Vol. 52 ›› Issue (2): 73-77.doi: 10.6040/j.issn.1671-7554.0.2013.689

• Articles • Previous Articles     Next Articles

Plasma thrombin-actived fibrionolysis inhibitor level  in gastric cancer and their clinical significances

WANG Li-li1, YU Chao2, XU Cheng-wei2   

  1. 1. School of Medicine, Shandong University, Jinan 250012, China; 
    2. Department of Laboratory Medicine, Second Hospital of Shandong University, Jinan 250033, China
  • Received:2013-11-15 Online:2014-02-10 Published:2014-02-10

PDF (PC)

200

Abstract:

 Objective   To explore the correlation between different stages of gastric cancer and the levels  of thrombin-activated fibrinolysis inhibitor (TAFI) and thrombin-antithrombin (TAT).  Methods  Blood samples were collected from 48 patients with gastric cancer (gastric cancer group), 34 patients with benign gastric disorders (benign gastric disorder group), and 50 healthy individuals (healthy control group). Plasma levels of TAFI, TAT, D-D and fibrinogen were measured using a chromogenic substrate method and ELISA. Then their correlations with different stages of gastric cancer were analyzed. The power of test and the best diagnostic value of TAFI and TAT were evaluated with receiver operating characteristic curve (ROC curve).  Results  Compared with healthy control group and benign gastric disorder group, the gastric cancer group had higher TAFI, D-D, fibrinogen, and TAT levels (P<0.05). When TAFI level was 28.85μg/mL, the sensitivity and specificity was 0.646 and 0.869, respectively. When TAT level was 31.50ng/mL, the sensitivity and specificity was 0.813 and 0.786, respectively. Conclusion  Patients with gastric cancer have significantly higher TAFI and TAT levels. TAFI and TAT are indicators of thrombosis tendency, which can be used to evaluate the risk of gastric cancer.

Key words: Thrombin-activated fibrinolysis inhibitor, Fibrinolysis, Gastric cancer, Thrombin-antithrombin complex

CLC Number: 

  • R735.2
[1] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47-52.
[2] DI Xuemin, NIU Shulei, ZHAO Jing, DU Sui, YU Huimin, ZHANG Hongtao, WANG Juan. CT-guided 125I seed implantation for lymph node metastases in patients with gastric cancer of later stage [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 79-84.
[3] ZONG Shuai, XIAO Dongjie, LIU Hua, JIA Yanfei, MA Xiaoli, LI Huanjie, LI Ping, ZHENG Yan, WANG Yunshan. Expression of CSN5 and its correlation with the prognosis of gastric carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 12-16.
[4] DONG Xiuhong. Effect of cognitive-behavioral therapy plus hypnosis in controlling cancer-related fatigue in gastric cancer patients receiving chemotherapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 56-59.
[5] ZHANG Shoucai, GAO Yu, ZHENG Guixi, YANG Yongmei, LIU Yanhong, GAO Yang, WANG Chuanxin. Diagnostic value of pepsinogen in atrophic gastritis and gastric cancer evaluation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(12): 46-52.
[6] LI Shuai, LI Dinuo, YUAN Chaofan, LIANG Xu, WANG Yubin. Inhibitory effect of miR-98-5p on human gastric cancer MGC803 cell proliferation by regulating AKT2 expression [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(11): 27-31.
[7] XU Guang-hui, LI Yu, LIU Zhong-lun, HU Nan. Correlations between serum levels of TP and clinical outcome in patients with advanced gastric cancer receiving S-1 regimen chemotherapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(S1): 77-79.
[8] YAN Bing1, LIU Guoqin2, JIANG Yongsheng2, SHEN Haiyu2, SUN Shaochuan2. Establishment of cisplatin-resistant gastric cancer cell line and the biological characteristics [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 49-52.
[9] GENG Chao1, PAN Ying-fang2, LIN Sen1. Eeffect of tumor necrosis factor-α-induced protein 8 on metastasis of gastric cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(5): 85-88.
[10] XIAO Jin-hua1, WANG Ya-ping1, ZHU Hua-yan1, PAN Yu-hong1, XU Qiu-lan2. Expression of serum HMGB1 and MMP-9 in early gastric cancer patients and its clinical significance [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(10): 70-73.
[11] WANG Sheng-jiang1， XU Cheng-wei2 . TAFI levels in patients with chronic liver diseases:
correlation with chronic hepatic damage [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(4): 83-.
[12] ZHANG Qi1,2, LI Yan-qing1, ZHANG Cui-ping2, ZHAO Kun2, SUN Xiang-hong3. Expression of activation induced cytidine deaminase and its
relationship with helicobacter pylori in the development
of intestinal-type gastric cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(12): 61-.
[13] LIU Bo-xue1, CHENG Huan-huan2, DONG Zhao-gang3, WANG Hua-yang2, YIN Zuo-hua3, SONG Qing-xu2. MB-WCX coupled with SELDI-TOF-MS: application to the diagnosis of gastric cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(9): 102-.
[14] TIAN Xiao-lin, LUO Qing-wei， JIANG Zhi-qing， LIN Jing. Expressions  of  VEGF-A, VEGF-D and podoplanin in gastric carcinoma and  their relationship with lymph node metastases [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(5): 61-.
[15] WANG Ze-jun1, XU Cheng-wei1, MA Xiao-li2, ZHENG Yan2, JIA Yan-fei2, XIAO Dong-jie2, WANG Yun-shan2 . Effect of CPB2 gene silencing on TAFI expression and   metastasis in breast cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(4): 57-.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd